Life-cycle, Economics, and Agronomy Division, Joint BioEnergy Institute, Emeryville, CA 94608.
Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720.
Proc Natl Acad Sci U S A. 2022 Jul 26;119(30):e2122309119. doi: 10.1073/pnas.2122309119. Epub 2022 Jul 19.
Plants and microbes share common metabolic pathways for producing a range of bioproducts that are potentially foundational to the future bioeconomy. However, accumulation and microbial production of bioproducts have never been systematically compared on an economic basis to identify optimal routes of production. A detailed technoeconomic analysis of four exemplar compounds (4-hydroxybenzoic acid [4-HBA], catechol, muconic acid, and 2-pyrone-4,6-dicarboxylic acid [PDC]) is conducted with the highest reported yields and accumulation rates to identify economically advantaged platforms and breakeven targets for plants and microbes. The results indicate that mass accumulation ranging from 0.1 to 0.3 dry weight % (dwt%) can achieve costs comparable to microbial routes operating at 40 to 55% of maximum theoretical yields. These yields and accumulation rates are sufficient to be cost competitive if the products are sold at market prices consistent with specialty chemicals ($20 to $50/kg). Prices consistent with commodity chemicals will require an order-of-magnitude-greater accumulation rate for plants and/or yields nearing theoretical maxima for microbial production platforms. This comparative analysis revealed that the demonstrated accumulation rates of 4-HBA (3.2 dwt%) and PDC (3.0 dwt%) in engineered plants vastly outperform microbial routes, even if microbial platforms were to reach theoretical maximum yields. Their recovery and sale as part of a lignocellulosic biorefinery could enable biofuel prices to be competitive with petroleum. Muconic acid and catechol, in contrast, are currently more attractive when produced microbially using a sugar feedstock. Ultimately, both platforms can play an important role in replacing fossil-derived products.
植物和微生物共享生产一系列生物制品的共同代谢途径,这些生物制品有可能成为未来生物经济的基础。然而,从未在经济基础上系统比较生物制品的积累和微生物生产,以确定最佳生产途径。对四种典型化合物(4-羟基苯甲酸[4-HBA]、儿茶酚、粘康酸和 2-吡喃酮-4,6-二羧酸[PDC])进行了详细的技术经济分析,采用了最高报道的产率和积累率,以确定植物和微生物具有经济优势的平台和盈亏平衡点。结果表明,质量积累在 0.1 到 0.3 干重%(dwt%)范围内,可以达到与微生物途径相当的成本,微生物途径的产率为最大理论产率的 40%至 55%。如果产品以与特种化学品一致的市场价格(20 至 50 美元/千克)出售,则这些产率和积累率足以具有成本竞争力。如果要与大宗商品化学品的价格一致,则植物的积累率或微生物生产平台的产率需要接近理论最大值的一个数量级。这种比较分析表明,工程植物中 4-HBA(3.2 dwt%)和 PDC(3.0 dwt%)的积累率远远超过微生物途径,即使微生物平台达到理论最大产率。它们作为木质纤维素生物炼制厂的一部分回收和销售,可以使生物燃料的价格与石油竞争。相比之下,粘康酸和儿茶酚目前使用糖原料进行微生物生产时更具吸引力。最终,这两个平台都可以在替代化石衍生产品方面发挥重要作用。